RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 157 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.96 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,937 | -33.0% | 906,767 | -34.6% | 0.25% | -30.8% |
| Q2 2023 | $10,353 | +11.8% | 1,385,950 | 0.0% | 0.36% | -10.2% |
| Q1 2023 | $9,259 | -99.9% | 1,385,950 | 0.0% | 0.40% | -24.2% |
| Q4 2022 | $10,685,675 | -27.5% | 1,385,950 | 0.0% | 0.53% | -36.7% |
| Q3 2022 | $14,747,000 | +561.9% | 1,385,950 | +406.5% | 0.84% | +419.3% |
| Q2 2022 | $2,228,000 | +13.7% | 273,650 | 0.0% | 0.16% | +89.4% |
| Q1 2022 | $1,959,000 | -56.0% | 273,650 | +5.3% | 0.08% | -47.2% |
| Q4 2021 | $4,453,000 | -25.5% | 259,941 | 0.0% | 0.16% | -17.0% |
| Q3 2021 | $5,981,000 | – | 259,941 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |